Table of Contents
AI-run disease detection and treatment coordination platform Viz.ai has introduced the completion of a $100 million Series D financing spherical at a business valuation of $1.2 billion. The round was led by Tiger Global and Perception Partners with the participation of prior investors which include Scale Ventures, Kleiner Perkins, Threshold, Google Ventures, Sozo Ventures, CRV, and Susa.
Relevant Content articles
AI health-related scan analyzer co Viz.ai raises $71m
The new funds, which have been raised as the quantity of hospitals working with the Viz System surpasses 1,000 with tens of millions of individuals served, will be utilised to aid Viz.ai’s progress, develop the platform to detect and triage more conditions, and increase its buyer foundation globally.
With places of work in San Francisco, Tel Aviv, Portugal and Amsterdam, Viz.ai was launched by CEO Dr. Chris Mansi and CTO Dr. David Golan. The company has pioneered the use of AI algorithms and device learning to improve the speed of prognosis and treatment for a selection of conditions in hospitals and health and fitness programs.
Mansi said, “Viz.ai is dedicated to assisting sufferers get improved, faster and a lot more equitable accessibility to life preserving solutions. We will continue on to devote closely in chopping edge technological innovation and expert services to integrate deeply into the medical workflow, enabling us to automate disease detection, raise diagnostic level and boost workflow across an total hub and spoke overall health method. More sufferers acquire the correct cure, resulting in superior individual results and enhanced money efficiency for the health and fitness process.”
Released by Globes, Israel company information – en.globes.co.il – on April 7, 2022.
© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.
